Back to Search
Start Over
459. Murine Study To Evaluate Long-Term Transgene Expression of the MSCV-MGMTP140K wc Retroviral Vector in Support of a Phase I Gene Transfer Trial-Limitations of the Murine Model as a Pre-Clinical Tool
- Source :
- Molecular Therapy. 13:S177-S178
- Publication Year :
- 2006
- Publisher :
- Elsevier BV, 2006.
-
Abstract
- Retroviral gene therapy vectors expressing the MGMTP140K transgene have been shown to protect hematopoietic cells from toxicity associated with a combined cancer treatment using 6-benzylguanine (6-BG) and an alkylating agent such as Temozolomide (TEM). In a Phase I gene transfer trial, high grade astrocytoma patients having poor prognoses using standard therapies, will undergo escalating dose treatments with 6-BG and TEM following MGMTP140K gene transfer into autologous hematopoietic stem cells. Although retroviral vectors are one of the most widely used vehicles for gene transfer, there is no uniformly accepted preclinical model defined to assess their safety, and, in particular their risk related to insertional mutagenesis. This study was designed as a murine pre-clinical study to assess the long term effects of the transduction of hematopoietic cells with the retroviral vector to be used in the clinical trial, MSCV-MGMTP140Kwc.
Details
- ISSN :
- 15250016
- Volume :
- 13
- Database :
- OpenAIRE
- Journal :
- Molecular Therapy
- Accession number :
- edsair.doi.dedup.....59b6dd495f13821425859e53d8752bc8
- Full Text :
- https://doi.org/10.1016/j.ymthe.2006.08.528